Brief: Alligator Bioscience, Orion Corporation Announce Exercise Of Development Option
May 11 (Reuters) - Alligator Bioscience AB ATORX.ST :
* ALLIGATOR BIOSCIENCE AND ORION CORPORATION ANNOUNCE
EXERCISE OF
DEVELOPMENT OPTION UNDER THEIR 2021 IMMUNO-ONCOLOGY RESEARCH
COLLABORATION AND LICENSE AGREEMENT
Source text for Eikon: ID:nMFN7w8rKK
Further company coverage: 271560.KS
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alligator Bioscience AB
See all newsSweden's Alligator Bioscience Q3 sales fall as R&D winds down
Brief: Alligator Bioscience Q3 EBIT SEK -19.3 Million
Brief: Alligator Bioscience Appoints Johan Gileus As CEO
Brief: Alligator Bioscience Announces Final Outcome In Rights Issue
Brief: Alligator Bioscience To Initially Receive SEK 58.8 Mln From Rights Issue